Resiquimod

Resiquimod, also known as R-848; S-28463; VML-600, is a n imidazoquinolinamine Toll-like receptor (TLR) agonist with potential immunostimulatory activity. Resiquimod binds to and activates TLRs 7 and 8, mainly on dendritic cells (DCs), macrophages, and B-lymphocytes, which results in the activation of the TLR signaling pathway and nuclear translocation of the transcription activator NF-kB another transcription factors; subsequently, the production of cytokines, especially interferon-alpha (INF-a), increases, enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans cells, which may result in enhanced activation of T-lymphocytes.

Properties:
Density: 1.28g/cm3
Boiling Point: 553.6ºC at 760mmHg
Flash Point: 288.6ºC
Refractive Index: 1.634
Vapor Pressure: 4.33E-13mmHg at 25°C

TLR Inhibitors Related Products:

TLR4-IN-C34; AMG9810; Resatorvid

[1]. Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526-32.

[2]. Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380-8.

[3]. Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role